Literature DB >> 18769028

Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter.

Hong Shen1, Yu Zhang, Hong Ding, Xu Wang, Lili Chen, Hualiang Jiang, Xu Shen.   

Abstract

GLUT4, the main insulin-responsive glucose transporter, plays a critical role in maintaining systemic glucose homeostasis and is subject to complicated metabolic regulation. GLUT4 expression disorder might cause insulin resistance, and over-expression of GLUT4 has been confirmed to ameliorate diabetes. Here, we reported that farnesoid X receptor (FXR) and its agonist chenodeoxycholic acid (CDCA) could induce GLUT4 transcription in 3T3-L1 and HepG2 cells. Furthermore, CDCA could increase the GLUT4 protein amount in C57BL/6J mice sex-dependently. The following progressive 5'-deletion analysis and site-mutation investigation further suggested that FXR could induce GLUT4 expression through FXR response element (FXRE) in the GLUT4 promoter. EMSA and knock-down of retinoid X receptor (RXR) indicated that FXR binds to the GLUT4-FXRE as a monomer and RXR does not participate in the FXR stimulation of GLUT4 expression. In addition, we demonstrated that FXR does not interfere with insulin-induced GLUT4 translocation to plasma membrane. All these data thereby implied that FXR is a new transcription factor of GLUT4, further elucidating the potential role for FXR in glucose metabolism. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769028     DOI: 10.1159/000149779

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  15 in total

Review 1.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

2.  Antifibrotic effect of total flavonoids of Astmgali Radix on dimethylnitrosamine-induced liver cirrhosis in rats.

Authors:  Yang Cheng; Jing-Yin Mai; Mei-Feng Wang; Gao-Feng Chen; Jian Ping
Journal:  Chin J Integr Med       Date:  2016-10-27       Impact factor: 1.978

Review 3.  Nuclear bile acid signaling through the farnesoid X receptor.

Authors:  Claire Mazuy; Audrey Helleboid; Bart Staels; Philippe Lefebvre
Journal:  Cell Mol Life Sci       Date:  2014-12-16       Impact factor: 9.261

Review 4.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

5.  FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.

Authors:  Sabrina Cipriani; Andrea Mencarelli; Giuseppe Palladino; Stefano Fiorucci
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

6.  Role of nuclear receptors in lipid dysfunction and obesity-related diseases.

Authors:  Hollie I Swanson; Taira Wada; Wen Xie; Barbara Renga; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci; Bo Kong; Ann M Thomas; Grace L Guo; Ramesh Narayanan; Muralimohan Yepuru; James T Dalton; John Y L Chiang
Journal:  Drug Metab Dispos       Date:  2012-10-04       Impact factor: 3.922

7.  Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.

Authors:  Ulrike Grienke; Judit Mihály-Bison; Daniela Schuster; Taras Afonyushkin; Markus Binder; Shu-hong Guan; Chun-ru Cheng; Gerhard Wolber; Hermann Stuppner; De-an Guo; Valery N Bochkov; Judith M Rollinger
Journal:  Bioorg Med Chem       Date:  2011-09-29       Impact factor: 3.641

8.  (+)-Rutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice.

Authors:  Yu Zhang; Haitao Zhang; Xin-Gang Yao; Hong Shen; Jing Chen; Chenjing Li; Lili Chen; Mingyue Zheng; Jiming Ye; Lihong Hu; Xu Shen; Hualiang Jiang
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

Review 9.  FXR an emerging therapeutic target for the treatment of atherosclerosis.

Authors:  Andrea Mencarelli; Stefano Fiorucci
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

10.  FXR induces SOCS3 and suppresses hepatocellular carcinoma.

Authors:  Fei Guo; Zhizhen Xu; Yan Zhang; Peng Jiang; Gang Huang; Shan Chen; Xilin Lyu; Ping Zheng; Xin Zhao; Yijun Zeng; Shuguang Wang; Fengtian He
Journal:  Oncotarget       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.